Literature DB >> 18302219

Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.

Jason M D'Antonio1, Changqing Ma, Federico A Monzon, Beth R Pflug.   

Abstract

BACKGROUND: Following androgen ablation therapy, the majority of prostate cancer patients develop treatment resistance with a median time of 18-24 months to disease progression.
METHODS: To identify molecular targets that promote prostate cancer cell survival and contribute to androgen independence, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and following the emergence of a highly proliferative, androgen-independent prostate cancer cell phenotype (LNCaP-AI).
RESULTS: We discovered alterations in gene expression for molecules associated with promoting prostate cancer cell growth and survival, and regulating cell cycle progression and apoptosis. Additionally, expression of AR co-regulators, adrenal androgen metabolizing enzymes, and markers of neuroendocrine disease were significantly altered.
CONCLUSIONS: These findings contribute greatly to our understanding of androgen-independent prostate cancer. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the adaptive response to androgen deprivation; it provides a more dynamic illustration of genes which contribute to disease progression in addition to specific genes which constitute an androgen-independent phenotype. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18302219     DOI: 10.1002/pros.20677

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  26 in total

1.  Schlafen 12 expression modulates prostate cancer cell differentiation.

Authors:  Pavlo L Kovalenko; Marc D Basson
Journal:  J Surg Res       Date:  2014-03-27       Impact factor: 2.192

2.  Classical and alternative nuclear factor-κB pathways: a comparison among normal prostate, benign prostate hyperplasia and prostate cancer.

Authors:  Chao Cai; Fu-neng Jiang; Yu-xiang Liang; Hui-chan He; Zhao-dong Han; Qi-shan Dai; Guo-qiang Qin; Jia-hong Chen; Xi-bin Chen; Yan-ru Chen; Guo-hua Zeng; Jian-guo Zhu; Wei-de Zhong
Journal:  Pathol Oncol Res       Date:  2011-04-16       Impact factor: 3.201

3.  Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods.

Authors:  Ji-Li Wang; Yan Wang; Guo-Ping Ren
Journal:  J Zhejiang Univ Sci B       Date:  2020 Mar.       Impact factor: 3.066

4.  lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.

Authors:  Peng Gu; Xu Chen; Ruihui Xie; Jinli Han; Weibin Xie; Bo Wang; Wen Dong; Changhao Chen; Meihua Yang; Junyi Jiang; Ziyue Chen; Jian Huang; Tianxin Lin
Journal:  Mol Ther       Date:  2017-05-06       Impact factor: 11.454

5.  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Authors:  Vassiliki Tzelepi; Eleni Efstathiou; Sijin Wen; Patricia Troncoso; Maria Karlou; Curtis A Pettaway; Louis L Pisters; Anh Hoang; Christopher J Logothetis; Lance C Pagliaro
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer.

Authors:  Trang Thi-Huynh Le; Chia-Ling Hsieh; I-Hsuan Lin; Cheng-Ying Chu; Anh Duy Do; Seu-Hwa Chen; Katsumi Shigemura; Koichi Kitagawa; Masato Fujisawa; Ming-Che Liu; Kuan-Chou Chen; Shian-Ying Sung
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

7.  Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia.

Authors:  Sebastian Meller; Anne Bicker; Matteo Montani; Kristian Ikenberg; Babak Rostamzadeh; Verena Sailer; Peter Wild; Dimo Dietrich; Barbara Uhl; Tullio Sulser; Holger Moch; Thomas A Gorr; Carsten Stephan; Klaus Jung; Thomas Hankeln; Glen Kristiansen
Journal:  Virchows Arch       Date:  2014-08-30       Impact factor: 4.064

8.  Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.

Authors:  Helen H L Chiu; Theresa M K Yong; Jun Wang; Yuwei Wang; Robert L Vessella; Takeshi Ueda; Yu-Zhuo Wang; Marianne D Sadar
Journal:  Cancer Lett       Date:  2009-12-30       Impact factor: 8.679

Review 9.  DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

Authors:  Jason M D'Antonio; Donald J Vander Griend; John T Isaacs
Journal:  Endocr Relat Cancer       Date:  2009-02-24       Impact factor: 5.678

10.  Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.

Authors:  Steven C Smith; Alexander S Baras; Charles R Owens; Garrett Dancik; Dan Theodorescu
Journal:  Cancer Res       Date:  2012-05-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.